accountPharma giant GlaxoSmithKline plc (NYSE:GSK) has done a dozen or so acquisitions and partnerships since Andrew Witty took over as CEO in May of 2008, and it would like to do more. But GSK R&D chief Moncef Slaoui (pictured) complains in an interview with Bloomberg published Friday that "desperate" rivals have are bidding the prices up too high.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Drug deals too pricey, says GSK exec
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account